{"name":"NeuroRx, Inc.","slug":"neurorx-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Lurasidone Oral Capsule","genericName":"Lurasidone Oral Capsule","slug":"lurasidone-oral-capsule","indication":"Schizophrenia","status":"phase_3"},{"name":"NRX-101 Oral Capsule","genericName":"NRX-101 Oral Capsule","slug":"nrx-101-oral-capsule","indication":"Acute suicidality in bipolar I or II depression (Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"Lurasidone Oral Capsule","genericName":"Lurasidone Oral Capsule","slug":"lurasidone-oral-capsule","phase":"phase_3","mechanism":"Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors to reduce psychotic symptoms and mood disturbances.","indications":["Schizophrenia","Bipolar I disorder depression","Major depressive disorder (adjunctive treatment)"],"catalyst":""},{"name":"NRX-101 Oral Capsule","genericName":"NRX-101 Oral Capsule","slug":"nrx-101-oral-capsule","phase":"phase_3","mechanism":"NRX-101 is a fixed-dose combination of d-cycloserine and lurasidone that modulates NMDA receptor function and dopamine/serotonin signaling to treat acute suicidality and bipolar depression.","indications":["Acute suicidality in bipolar I or II depression (Phase 3)","Bipolar depression with suicidal ideation"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxOVU9SN0dsTDFubGhmQ0RuSXVLU3pLOTR3XzBsX1VoYkl0c0M2dmttR25vUGduMXdYeE41YXZMQkhaWVJoTnc4UjFONnRvX2pDdzE0YUNQOTVrUFYzeGRvV2MtT1lpMTFyNW00TjJLZDFuaG1ncmJiWkRPaHVOVkFEbFhmSGxwNHRpOGMzWUhlZ25XZlV1d2tTVWp6WEpuRmEwbHc5bkRqRUVPaEhGcGZINGhSRHFFUV9mOTNoT0FDRjNfZGVvbGpuMnJUWjdLU1lnczFiWkRWa1lGRFl2azRhUEVSdG5GQk1EUWJIYUdCbHJ6T2VreFB6dnQ0TQ?oc=5","date":"2026-03-25","type":"regulatory","source":"Sahm","summary":"NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress - Sahm","headline":"NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQVUltOFBsMEx5Rng5d0ozUkFlaEZwYmp5VDZucXlJZmRENWZ2V1FLdkw0WU4zNWc1R1p6QkpsOVlZQVRHbWxrRG9FdTJTNVltR1owUXVaX0tMNS1xbURRZzlObGszM2lfOE1DRnA2VHdUSF9XOU41UzNTN0s2aXZNcm4wbURudlBWeFlqVkhCVGp1a2hVeWVnNU4yekRiekFIQXU0MzRtSWxwcGl3OXIzMWdEamZmLVNMa290Wmw1X2dnMFQzckdOTGVB?oc=5","date":"2026-03-24","type":"regulatory","source":"citybiz","summary":"NRx Pharmaceuticals Announces Full-Year 2025 Results with Commercial and Regulatory Updates - citybiz","headline":"NRx Pharmaceuticals Announces Full-Year 2025 Results with Commercial and Regulatory Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOOXloOWRZYWlJM0diVDNzclozWm9SblFXXzU0RDI2MTdPVHR2QWxLd0VpNkhfczlqQ1J2cVVyLUxLclVNZGdfU0l4Vk9ITEpsNkNwelJSdGFVTFZlVTNXWUxQRVBlazBNa21fcUQ3MXR3QklrZVNpWElrcm5QalNUeXpGSWlRMnpQQk1MTk44dEJKYWs4QlltZWQtRjBwczJyQS1keE5UTUw4cWJLa0JSZERzaUJEMHJQaTFvSFpPVQ?oc=5","date":"2026-03-24","type":"pipeline","source":"Stock Titan","summary":"NRx says it can fund operations through 2026 as ketamine review advances - Stock Titan","headline":"NRx says it can fund operations through 2026 as ketamine review advances","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQNEhmNGt6ajE1YUk5QTdkQ2ZNR1k1WkI1VUN0TFExcnNWaW1ZcW9qTTR2Xy1jRG54akxoUjd4WGJ5dzdtdVhiaGJCUGFweExpa2dCWG51MG12ZElkQTBIZi0wRlhKZzNxUDhkdGRhaWVOU0Q0clpqdzlmR05WazFiYmkzRVVXR29rSFJZVktXZE9MRkhHbkEyQTNfdw?oc=5","date":"2025-03-18","type":"pipeline","source":"Fierce Biotech","summary":"Clario continues acquisition spree with imaging specialist NeuroRx - Fierce Biotech","headline":"Clario continues acquisition spree with imaging specialist NeuroRx","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxPVFhDRldlZ1diR05MYnFhM1F0TmNyS3RHb1NfSkpRUXJWemE4VHVxdmlQVUJNUVh1WFpLM3VIeVkzMHAxNDEwYUd2NndlbUQ0SUhEM2dkN0NtaFVMdVpabkhEdWRxQ08xVWt0Rkx2d1llUnEwbDVqUDVaMnRmYXpUbmpLdTFaTDRqMl9BZDgtamZBZ0hJNVpUS1AyektWX1ZiMFprTU9YWjJsaHlabmNrYmNoNHRGUHNXVF9pX2tHRGFaYjdBWElTcS1pVEZIV1Fad1RUNUdTc01pMll1c2k1YlZjUS1hWFUtb2tyeGx3Wm1PWTRX?oc=5","date":"2024-04-15","type":"pipeline","source":"prnewswire.com","summary":"NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) - prnewswire.com","headline":"NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxPdkRjWk9xNDFIZmlnRkgwcTViMzVObE5Ma1laNG1nV3U3M2Rwel9sRG5MNXY1dEpkWC1vMmwtS29YYkJsT3dlZ1BHcU13anpWekVCUjhkUjlUSUp6OEE4Z1ByaWpNZUM5OWJicGg4UkRIektkWTJOX3JMSzRIV3dyNWV0V1NnR3E2ZE9KRDh0YXhyV21kNXdVY2drcWdTc3hOeE1rS3NKV1BZT2JsQ0dUSnZielJERnpTME0zWEdkOEdNUlNqbHZMQnZIbDlpcGFITlhtRDlxUkRtSVZiRHZRcXZGMm1UajFNVWxRX2FENHhtU21sTzFPdGVxeC13S3l1NldZNnJMT3M1bFBRbGpFNU5rOE1KSDg?oc=5","date":"2023-02-22","type":"patent","source":"prnewswire.com","summary":"NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions - Adds New U.S. Patent to Portfolio - prnewswire.com","headline":"NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions - Adds New U.S. Paten","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPR2tmcno4OEp6YWlxX21nUVlSbkFGaTNlVk5vVm1xSWs1Y2pad2FFOVNmb01DaGNVRTN6enNGelQxQk80OWJsQTBFZElUZm5zVzRiMENYVmwxSk5Ob2d4RkZURGNxQWpuNWtJRmlDREE3MHhrMTcwX0d4WG1zek9NY2hBZXQxWVVKXzU3RnBoVHBwaTYwX3Axc3hzREc1d3NQUjMzeTNrd215ZEE?oc=5","date":"2022-03-09","type":"pipeline","source":"The Business Journals","summary":"NRx Pharmaceuticals on search for new CEO - The Business Journals","headline":"NRx Pharmaceuticals on search for new CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNTHljZXkyVzRFNElsY3Z2NEs1SHFqTnlCRGpnbGJ4V3JyTUlVM2pHenp6MVhDWV9KOVUxTnlqNWR5b2xLVFVjMVlfa2Z1M0RhVDBQTm03MEtQOEhxd3V3RWZteFZiaFlqeDEwMFMxa1YyUEVXdlk2TUNYV1dlRzJnUVNLZk44NmRjRUpfZ1pqQ2JrazFOeXk5eTRfNXpoOUhkcWhHUzhxQ3RFUUItVk1qdkRwcG55NnZTNzRLRll2ZjJBZVI4THl2Vm4tOVFyYWd1ZWtuQWp2dzBPeWktNTRDV2RTdHl5S0Z0Y1R2OG5oMU9jeGM0RnZ2bUVKN1FHUEltR0w0Z2psWHlFVVNIcm1YOWlKSXo4WTBfT2NkcXlmOG9uMGhhNllmRmJR?oc=5","date":"2021-05-25","type":"deal","source":"prnewswire.com","summary":"NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA) - prnewswire.com","headline":"NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOdWZNU2FkWEc3S2Z3VmtOTVBYZG5QcDVJTXYzVWdpZmxpWE1BSVJBejd3QWUyd1JGbUkzLWc4MlBfdGR3QkVWRmtJdWFJcHAwZ0syMk9yOHZpUXFrQzdud3dOZzhGa2JWUE1WY21HMFhmaFZUS1VpcW1LZ20zd19Hc1pEQWYyay1IVXhHOFBTVHRTMWR2MkdwU0o1NVFhQQ?oc=5","date":"2021-05-25","type":"deal","source":"drugdeliverybusiness.com","summary":"NeuroRx completes merger with SPAC, starts trading on Nasdaq - drugdeliverybusiness.com","headline":"NeuroRx completes merger with SPAC, starts trading on Nasdaq","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPZ0RCQm1QbDhYWGZKUk1LS2pSLVh6QjYxb0RTc3BaUGFVcWhfbkZOcHhJWkFSNmJtejlleWlscGhGQ2FmckgwVlpUVEIyenVMaXdTdnpId0NCMTd2S3NDcnBXa2tPM0o1eXJPUnBfZXV5cHEtc3hNVUM5NlFYczlHRDlhMnAzcDJqRXdvbzNveGFyaGV5X0RrOS1rQlNUbkJ6Z3AwVWxMRHNrTF9JX241eU1DY1gtWGN6NENNcHF6akpKWENENW9aSlpITEFoemtuMlpuRDhiYUMyZw?oc=5","date":"2021-04-19","type":"pipeline","source":"prnewswire.com","summary":"NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development - prnewswire.com","headline":"NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQdTdsdmdSSk5TMV9WRFpERkRfclZkM1NNNDNuQW1UQjR5VHlFT01OV0NRT3BHYzVqT2J4S29uNWhXNGRMRmlZZkpIVEhPN01OZzRGNXRNMzd6UzcwdTZNUFpCbllpaV9lcHVXZGpZd2JxeVdYQ0ZkbWdmVVllc1dyNXdKc2pTemNud1dnb3R3NlFGVm1nVW1qdTF3?oc=5","date":"2021-01-14","type":"pipeline","source":"BioSpace","summary":"NeuroRx on the Move: An Interview with Founder and CEO Jonathan Javitt - BioSpace","headline":"NeuroRx on the Move: An Interview with Founder and CEO Jonathan Javitt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxON2l1UWtqekdBUGw4cXJBOVYxVDZXX1ZYQjY3SVFqaUVUZkZmYWo4Vzh2MmVQVExNU1dyejZrQkFTc0hyRDA1Y3V0eTVsOV9odzhqWkREVmYxQWNIc09MUnFLd0toblBkemI1X1lUaW1wVUZYUXo4Ykt2Y3B4N2FOTG1PZV9DZWVfM2hEeGtVNE9SRmFHMk81dTlkdDd3bzRhQmMyeXgxQ1ZJdk5wVE9yS2RYaHh5UTktclZoVmtzLXRuLW5LY1MyTnhDZXlCbURUclpnMjBUSzdXVmRCNkhRMlo3NmhmUQ?oc=5","date":"2019-10-23","type":"pipeline","source":"prnewswire.com","summary":"NeuroRx Secures HK$ 750 Million Capital Commitment From The Gem Group for Development of NRX-101 - prnewswire.com","headline":"NeuroRx Secures HK$ 750 Million Capital Commitment From The Gem Group for Development of NRX-101","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}